File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Induction of broader protection against influenza A virus by sequential-boosting of inactivated influenza vaccines in Balb/c mouse
Title | Induction of broader protection against influenza A virus by sequential-boosting of inactivated influenza vaccines in Balb/c mouse |
---|---|
Authors | |
Issue Date | 2016 |
Publisher | International Society for Influenza and other Respiratory Virus Diseases. |
Citation | Options IX for the Control of Influenza Conference, Chicago, USA, 24- 28 August 2016, abstract# P-186 How to Cite? |
Abstract | Background: The continuous threat of unpredictable influenza virus outbreaks in human necessitates the investigation of new types of vaccines that target a comprehensive range of influenza viruses. However, the current vaccine formulations should always be updated annually for the upcoming influenza season and this shortcoming is mainly because such vaccines only enable a very limited level of homologous and heterologous protection. Therefore, novel vaccines are needed that target the conserved viral proteins which provide a broader immunity against influenza. These vaccine methodologies can lead to the development of universal protection against influenza. Aim: To compare the magnitude of the homologous and heterologous protection developed by sequential-boosting influenza vaccine strategy. Method: BALB/c mice were immunized intramuscularly with 2 or 4 doses (3 weeks interval) of inactivated whole influenza A virus antigen combined with adjuvant (Group A: seasonal H1N1/Brisbane/07-pandemic H1N1/California/09-PBS-PBS, Group B: seasonal H1N1/Brisbane/07-pandemic H1N1/California/09-H5N1/Vietnam/04-H5N1/Vietnam/04, (-) Control: PBS-PBS- PBS-PBS). 3 weeks post-vaccination, a lethal dose of pandemic H1N1/PR/8 or H3N2/HK/68 (10LD50) was given intranasally, and weight loss (21 dpi), morbidity were monitored. The lung viral titers (in both Day 3 and Day 7 post-infection) were measured by TCID50 assay. Specific Ab measurement using different hemagglutinin (HA) proteins was conducted using an ELISA assay format. Results: Significantly different kinetics against both homologous and heterologous infection between the two groups was seen (P<0.05), which were demonstrated by less weight loss and morbidity in Group B (H1N1/PR/8 challenge: survival ratio is in 55.0% in A, 100% in B; H3N2/HK/68 challenge: survival ratio is 33.3% in A, 91.7% in B). Furthermore in Group B, the lung viral load during the challenge represented a faster clearance of influenza virus (for both H1N1/PR/8 and H3N2/HK/68 challenge, P<0.05). Meanwhile, reduced clinical morbidity in Group B was partially associated with higher HA antibody generation (for H1N1/PR/8, A Vs B, P<0.05). Conclusion: The presence of an enhanced homologous and heterologous protection after sequential-boosting influenza A vaccine in mouse model may assist in the development of a potential strategy of future influenza prophylactics. |
Description | Poster session - Abstract# P-186 |
Persistent Identifier | http://hdl.handle.net/10722/261246 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yan, L | - |
dc.contributor.author | Doak, SA | - |
dc.contributor.author | Poon, LML | - |
dc.date.accessioned | 2018-09-14T08:54:57Z | - |
dc.date.available | 2018-09-14T08:54:57Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Options IX for the Control of Influenza Conference, Chicago, USA, 24- 28 August 2016, abstract# P-186 | - |
dc.identifier.uri | http://hdl.handle.net/10722/261246 | - |
dc.description | Poster session - Abstract# P-186 | - |
dc.description.abstract | Background: The continuous threat of unpredictable influenza virus outbreaks in human necessitates the investigation of new types of vaccines that target a comprehensive range of influenza viruses. However, the current vaccine formulations should always be updated annually for the upcoming influenza season and this shortcoming is mainly because such vaccines only enable a very limited level of homologous and heterologous protection. Therefore, novel vaccines are needed that target the conserved viral proteins which provide a broader immunity against influenza. These vaccine methodologies can lead to the development of universal protection against influenza. Aim: To compare the magnitude of the homologous and heterologous protection developed by sequential-boosting influenza vaccine strategy. Method: BALB/c mice were immunized intramuscularly with 2 or 4 doses (3 weeks interval) of inactivated whole influenza A virus antigen combined with adjuvant (Group A: seasonal H1N1/Brisbane/07-pandemic H1N1/California/09-PBS-PBS, Group B: seasonal H1N1/Brisbane/07-pandemic H1N1/California/09-H5N1/Vietnam/04-H5N1/Vietnam/04, (-) Control: PBS-PBS- PBS-PBS). 3 weeks post-vaccination, a lethal dose of pandemic H1N1/PR/8 or H3N2/HK/68 (10LD50) was given intranasally, and weight loss (21 dpi), morbidity were monitored. The lung viral titers (in both Day 3 and Day 7 post-infection) were measured by TCID50 assay. Specific Ab measurement using different hemagglutinin (HA) proteins was conducted using an ELISA assay format. Results: Significantly different kinetics against both homologous and heterologous infection between the two groups was seen (P<0.05), which were demonstrated by less weight loss and morbidity in Group B (H1N1/PR/8 challenge: survival ratio is in 55.0% in A, 100% in B; H3N2/HK/68 challenge: survival ratio is 33.3% in A, 91.7% in B). Furthermore in Group B, the lung viral load during the challenge represented a faster clearance of influenza virus (for both H1N1/PR/8 and H3N2/HK/68 challenge, P<0.05). Meanwhile, reduced clinical morbidity in Group B was partially associated with higher HA antibody generation (for H1N1/PR/8, A Vs B, P<0.05). Conclusion: The presence of an enhanced homologous and heterologous protection after sequential-boosting influenza A vaccine in mouse model may assist in the development of a potential strategy of future influenza prophylactics. | - |
dc.language | eng | - |
dc.publisher | International Society for Influenza and other Respiratory Virus Diseases. | - |
dc.relation.ispartof | ISIRV Options IX for the Control of Influenza Conference | - |
dc.title | Induction of broader protection against influenza A virus by sequential-boosting of inactivated influenza vaccines in Balb/c mouse | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Yan, L: ylmeng@hku.hk | - |
dc.identifier.email | Doak, SA: sophiev@hku.hk | - |
dc.identifier.email | Poon, LML: llmpoon@hkucc.hku.hk | - |
dc.identifier.authority | Doak, SA=rp02141 | - |
dc.identifier.authority | Poon, LML=rp00484 | - |
dc.identifier.hkuros | 291116 | - |
dc.publisher.place | Chicago, IL | - |